|
The two companies plan to launch a new dermatological HA filler brand, ‘LU CHAENA’, in Korea in the third quarter of this year. Designed for both lifting and volume enhancement, LU CHAENA incorporates BioPlus’s internationally recognized technology, which has already obtained CE certification. Through years of research into local treatment trends, the product is optimized to improve facial volume quickly and non-invasively, with fine-tuned viscosity and elasticity.
Unlike traditional fillers that merely fill deep wrinkles, LU CHAENA spreads evenly upon injection and is designed to degrade slowly, allowing sustained collagen production. It aligns with the growing domestic interest in ‘slow-aging’ solutions, contributing to the rapid growth of Korea’s premium HA filler market.
Daniel Youn, Head of Marketing Strategy at BioPlus, commented,
“This domestic launch marks a major milestone for DVS-based premium HA fillers, which have already been recognized for their safety, ease of use, and longevity in global markets.
Looking ahead to 2025, we are accelerating the launch of our botulinum toxin product.
Furthermore, by leveraging our exclusive next-generation growth factor peptide ‘Hugro Peptide’. we are expanding into the skin booster market under the ‘Kiara’ brand and entering the premium derma-cosmetic sector with ‘Bonyx’.
These integrated initiatives will reinforce our business synergy across multiple categories.”
With this MOU, BioPlus and Generation aim to reinforce the competitiveness of local brands in the Korean medical aesthetics market and usher in a new era of innovation for premium injectable products.
